Key facts
- It has raised $13.8M; the latest was Early Stage VC in Dec 2025.
- Notable investors include Sequoia Capital, HSG (Hong Kong), ZhenFund, Green Pine Capital Partners, Capital Science and Technology Development Group — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Beiqi Biology
- ·The full record, as it builds
Funding rounds
No funding rounds for Beiqi Biology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beiqi Biology
Developer of biopharmaceutical products designed for therapeutic research and clinical application. The company offers molecular biology techniques, drug discovery processes, and laboratory-scale production with features such as targeted compound development, controlled testing environments, and standardized quality management systems, enabling healthcare institutions and research organizations to advance treatment development, improve clinical outcomes, and maintain compliance with regulatory requirements while supporting innovation in biomedical science.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2022
- Website
- beicelltherapeutics.com/
- Ownership
- Privately Held (backing)
Beiqi Biology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beiqi Biology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beiqi Biology in its N-PORT filings yet. We sweep new filings monthly.